Ioglucomide: a new nonionic myelographic agent. Preclinical studies.
Ioglucomide, a new iodinated nonionic contrast medium directed primarily toward myelographic use, was subjected to an extensive toxicological examination in animals. In the majority of studies, ioglucomide was compared directly with metrizamide. In some respects, including freedom from production of arachnoiditis, ioglucomide and metrizamide were comparable. However, acute toxicity after intravenous injection or instillation into cerebrospinal fluid was significantly less for ioglucomide. Also, in contrast to metrizamide, ioglucomide produced no evidence of any type of convulsive activity after subarachnoid administration. The improved safety of ioglucomide could not be related to osmolality; therefore, the importance of osmolality for nonionic myelographic agent safety is questioned.
D000818:Animals; D001921:Brain / Q000187:drug effects; D003287:Contrast Media; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005069:Evaluation Studies as Topic; D007275:Injections, Intravenous; D007463:Iodobenzoates / Q000008:administration & dosage / Q000009:adverse effects; D007700:Kinetics; D007928:Lethal Dose 50; D008578:Meninges / Q000187:drug effects; D008793:Metrizamide / Q000008:administration & dosage / Q000009:adverse effects; D051379:Mice; D009192:Myelography / Q000009:adverse effects / Q000379:methods*; D011817:Rabbits; D051381:Rats; D014283:Triiodobenzoic Acids / Q000008:administration & dosage / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C031376:ioglucomide; D008793:Metrizamide